Evidence map›Paper›PMID 41488597›Full record

ArticleInternational journal of cardiology. Heart & vasculature2026

Genetic anticipation and cardiac conduction abnormalities in myotonic dystrophy type 1: implications for early stratification from a multicenter registry.

Rebeca Lorca, Alberto Alen, Carlos Moliner-Abós, Fernando de Frutos, Néstor Báez-Ferrer, María Luisa Peña-Peña, Eduardo Villacorta, Tomas Ripoll-Vera, Esther Zorio, Aaron Martínez-Gimeno and 17 more

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Rebeca LorcaÁrea del Corazón, Hospital Universitario Central Asturias, 33011 Oviedo, Spain.
Alberto AlenÁrea del Corazón, Hospital Universitario Central Asturias, 33011 Oviedo, Spain.
Carlos Moliner-AbósCardiology Department, Hospital de la Santa Creu i Sant Pau, IIb-SantPau, CIBERCV, Universitat Autónoma de Barcelona, Barcelona, Spain.
Fernando de FrutosHeart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Néstor Báez-FerrerCardiology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
María Luisa Peña-PeñaUnidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Eduardo VillacortaInherited Heart Disease Unit Cardiology Department, Hospital Universitario Álvaro Cunqueiro, Spain.
Tomas Ripoll-VeraInherited Heart Disease Unit, Hospital Universitario Son Llatzer & IdISBa. Palma de Mallorca, Spain.
Esther ZorioCIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain.
Aaron Martínez-GimenoDepartment of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
José Bermúdez-JiménezDepartment of Cardiology, Virgen de las Nieves University Hospital, Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.
Javier LimeresCIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain.
Coloma TironInherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitari Dr Josep Trueta, Girona, Spain.
José M Larrañaga-MoreiraInherited Cardiac Disease Unit, Hospital Universitario de A Coruña (HUAC), Servizo Galego de Saúde (SERGAS), Spain.
Eva Cabrera-RomeroInstituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña (UDC), A Coruña, Spain.
Pablo García-PavíaCIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain.
María Angeles EspinosaCIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain.
Jesús PiquerasUnidad de Cardiopatías Familiares e Insuficiencia Cardiaca, Hospital General Universitario de Ciudad Real, Spain.
Soledad García-HernándezSan Cecilio University Hospital, Granada, Spain.
Julián Palomino-DozaCIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain.
Marc Soriano-AmoresCardiology Department, Hospital de la Santa Creu i Sant Pau, IIb-SantPau, CIBERCV, Universitat Autónoma de Barcelona, Barcelona, Spain.
German MorisInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Lidia María Carrillo-MoraUnidad CSUR/ERN de Cardiopatías Familiares, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Petros SyrisCentre for Heart Muscle Disease, UCL Institute of Cardiovascular Science, United Kingdom.
Rut Alvarez-VelascoÁrea del Corazón, Hospital Universitario Central Asturias, 33011 Oviedo, Spain.
Juan Ramón GimenoUnidad CSUR/ERN de Cardiopatías Familiares, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Carmen MuñozUnidad CSUR/ERN de Cardiopatías Familiares, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: DM1 is an autosomal dominant disorder caused by unstable CTG repeats that expand over lifetime and in successive generations, contributing to genetic anticipation. Cardiac conduction abnormalities (CCAs) are a major source of morbidity and premature death in DM1, yet the influence of age at diagnosis, generation, and CTG repeat length on the timing and progression of cardiac involvement remains poorly defined. Method: This multicentric retrospective study included 549 adult DM1 patients from 16 hospitals in Spain. The primary composite endpoint comprised significant CCAs, device implantation, malignant ventricular arrhythmias and cardiac syncope. Patients were stratified by age‑at‑diagnosis (<40, 40-59, and ≥60 years); birth generation (1920-1965, 1966-1990, 1991-2015), and CTG repeat length (<100, 100-599, and ≥600). Results: During follow‑up, 33.1 % of patients experienced the primary endpoint. This risk was 4.7‑fold higher in the youngest group versus the oldest group (HR 4.70; p < 0.001); 35‑fold higher in the 3rd generation versus the 1st and increased progressively with longer CTG expansions. Device implantation rates were likewise higher in younger patients, later generations, and those with larger repeat lengths. Conclusion: The results demonstrate a striking anticipation pattern in the cardiac phenotype of DM1, with progressively earlier and more severe electrical disease paralleling CTG expansion across generations. Incorporating age at diagnosis, generational cohort, and genetic repeat burden into clinical assessment may enhance risk stratification and enable earlier, targeted rhythm surveillance and device therapy to prevent sudden cardiac death in DM1.

Indexed as

Cardiac conduction abnormalities (CCA)Cardiovascular geneticsInherited cardiac diseaseMyotonic dystrophy type 1 (DM1)Sudden cardiac death (SCD)

Identifiers

PMID41488597
PMCPMC12757560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.